Table 4.

Relative risk of hepatotoxicity associated with individual MMI or CBM compared with PTU

	Events/PTU users	Events/MMI users†	Events/CBM users†	MMI vs. PTU	CBM vs. PTU
				Adjusted HR (95% CI)*	Adjusted HR (95% CI)*
Hepatitis	21/24 941	107/34 361	11/12 077	3.54 (2.21, 5.65)‡	1.04 (0.50, 2.16)
Acute liver failure	12/24 941	9/34 361	3/12 077	0.55 (0.23, 1.32)	0.53 (0.15, 1.88)
Cholestasis	4/24 941	6/34 361	3/12 077	1.04 (0.29, 3.72)	1.41 (0.31, 6.33)

CBM, carbimazole; CI, confidence interval; HR, hazard ratio; MMI, methimazole; PTU, propylthiouracil.

^*Adjusted for all variables listed in Table 1, with the exceptions of history of hyperthyroidism, hyperlipidaemia and use of neurological drugs for the outcome of acute liver failure as well as presence of pregnancy and chronic kidney diseases for the cholestasis outcome due to small sample size.

^†The censorship of switch between use of MMI and CBM was considered during analyses of hepatotoxicity risk from individual MMI or CBM.

^‡P < 0.05.